On 15 June 2022, the 2022 Future Healthcare 100 list, jointly launched by VB100, Artery.com and Eggshell Research Institute, was officially released. As a leading innovator in China, magAssist was elected as one of the 2022 Future Healthcare 100 main list "Top 100 Innovative Medical Devices in China" with its product MoyoAssist Extra-VAD.
Innovation is the root of the development of a country and a nation, but also the source of medical device development. At present, there is still a "neck" phenomenon in the cutting-edge technology of the domestic medical device industry, and the problems of insufficient innovation in cutting-edge fields and the lack of core components are particularly prominent. It is clearly pointed out in the national 14th Five-Year Plan to achieve breakthroughs in the core technology of high-end medical equipment and accelerate the import substitution.
Within three years since its establishment in 2017, magAssist has brought first product MoyoAssist Extra-VAD to the clinical stage, which has already saved the lives of several patients. Meanwhile, magAssist aims to develop multi-pipelines and platform-based solutions for patients. Besides extra-VAD, other pipelines including percutaneous ventricular assist device (p-VAD), the new generation ECMO system and organ care system are all in the pre-clinical development stage aiming to fill the technology blank in China.
magAssist's contribution in the medical device field is evident to all and has become an industry
benchmark. In 2021, magAssist has completed a Series B round of over RMB 100 million and a Series C round of nearly RMB 500 million, which is highly favored by capital. In the past year, we have been invited to attend the 47th European Society for Artificial Organs (ESAO) Congress and the International Society for Mechanical Circulatory Support (ISMCS), which are the most authoritative academic conferences in the field of artificial organs in the world. In the future, magAssist will continue to forge ahead and continue to cultivate in the field of extracorporeal life support to create greater value for society.
About the "Future Healthcare 100" list
The Future Healthcare 100 list is the first list of innovative healthcare companies in China launched by VB100, Artery.com and Eggshell Research Institute for non-listed companies. It aims to select Chinese innovative healthcare players that truly represent the future of healthcare, discover the core strengths of China's future healthcare industry, and promote the process of innovative changes in the healthcare industry.
The list is open to non-listed companies in the healthcare sector. Based on the VB100 value assessment model, the top 100 innovative companies in the valuation ranking will be selected from four major fields: healthcare services, digital healthcare, medical devices and biomedicine, through the process of self-declaration by companies, review by VB100 review board, cross-review by supporting organizations and final review by expert committee. In addition to the valuation, the growth and annual performance of the candidates will be examined in four primary indicators, including human resources, knowledge resources, key partner resources and market performance, with a total of 17 secondary indicators.
